Integrative proteomics in prostate cancer uncovers robustness against genomic and transcriptomic aberrations during disease progression.

导出 OA

翻译打印收藏纠错

作者： Leena,Latonen ^[1] ; Ebrahim,Afyounian ^[2] ; Antti,Jylhä ^[1] ; Janika,Nättinen ^[3] ; Ulla,Aapola ^[3] ; Matti,Annala ^[3] ; Kati K,Kivinummi ^[1] ; Teuvo T L,Tammela ^[1] ; Roger W,Beuerman ^[4] ; Hannu,Uusitalo ^[3] ; Matti,Nykter ^[5] ; Tapio,Visakorpi ^[6]

作者单位： Prostate Cancer Research Center, Faculty of Medicine and Life Sciences and BioMediTech Institute, University of Tampere, Tampere, 33014, Finland. ^[1] FimLab Laboratories, Tampere University Hospital, Tampere, 33101, Finland. ^[2] Department of Ophthalmology, Faculty of Medicine and Life Sciences, University of Tampere, Tampere, 33014, Finland. ^[3] Department of Urology, University of Tampere and Tampere University Hospital, Tampere, 33521, Finland. ^[4] Singapore Eye Research Institute, Singapore, 169856, Singapore. ^[5] Duke-NUS Neuroscience, Singapore, 169857, Singapore. ^[6] Duke-NUS Medical School Ophthalmology and Visual Sciences Academic Clinical Program, Singapore, 169857, Singapore. ^[7] Ophthalmology, Yong Loo Lin Medical School, National University of Singapore, Singapore, 119228, Singapore. ^[8] Tays Eye Centre, Tampere University Hospital, Tampere, 33521, Finland. ^[9] Prostate Cancer Research Center, Faculty of Medicine and Life Sciences and BioMediTech Institute, University of Tampere, Tampere, 33014, Finland. matti.nykter@uta.fi. ^[10] Science Center, Tampere University Hospital, Tampere, 33521, Finland. matti.nykter@uta.fi. ^[11] Prostate Cancer Research Center, Faculty of Medicine and Life Sciences and BioMediTech Institute, University of Tampere, Tampere, 33014, Finland. tapio.visakorpi@uta.fi. ^[12] FimLab Laboratories, Tampere University Hospital, Tampere, 33101, Finland. tapio.visakorpi@uta.fi. ^[13]